Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. Its products include Nidlegy, Fibromun, Darleukin, Dodekin, Onco IX, Tripokin, OncoFAP, and Dekavil. The company was founded by Dario Neri, Duccio Neri, and Giovanni Neri in 1996 and is headquartered in Siena, Italy.